References
- Semple D, Smyth R, Burns J, Darjee R, Mclntosh A. Symptoms of psychiatric illness, schizophrenia and related psychosis. Oxford handbook of psychiatry, L Beauclair, R Miller, L Annable. Oxford University Press Inc, New York 2005; 90–210
- Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive Dyskinesia in the era of typical and atypical antipsychotics. Canadian Journal of Psychiatry 2005; 50: 703–714
- Gelder M, Harrison P, Cowen P. Drugs and other physical treatments. Shorter Oxford textbook of psychiatry. Oxford University Press Inc, New York 2006; 534
- Kane JM. Tardivedyskinesia: Epidemiological and clinical presentation. Psychopharmacology: The fourth generation of progress, E Borroni, DJ Ksnmr. Raven Press Ltd, New York 1995; 1485–1495
- Glazer WM, Morgenstern H, Doucette JT. Predicting the long term risk of tardive dyskinesia in outpatients maintained on neuroleptic medication. Journal of Clinical Psychiatry 1993; 54: 133–139
- Jeste DV. Tardive dyskinesia in older patients. Journal of Clinical Psychiatry 2000; 61(suppl 4)27–32
- Llorca PM, Chereau I, Bayle FJ, Lancon C. Tardive dyskinesia and antipsychotics: A review. European Psychiatry 2002; 17: 129–138
- Barnes TRE. A rating scale for drug -induced akathisia. British Journal of Psychiatry 1989; 154: 672–676
- Simpson GN, Angus JWS. A rating scale for extra pyramidal side effects. Acta Psychiatrica Scandinavica 1970; 212(suppl 44)11–19
- Guy W. ECDEU assessment manual for psychopharmacology. Rev. ed. US Department of Health, Education and Welfare, Washington DC 1976
- Gervin M, Barnes TRE. Assessment of drug-related movement disorders in schizophrenia. Advanced Psychiatric Treatment 2000; 6: 332–341
- Lane RD, Glazer WM, Hansen TE, Berman WH, Kramer S. Assessment of tardive dyskinesia using the abnormal involuntary movement scale. Journal of Nervous and Mental Disease 1985; 173: 353–357
- Munetz MR, Benjamin S. How to examine patients using the abnormal involuntary movement scale. Hospital and Community Psychiatry 1988; 39: 1172–1177
- Schooler NR, Kane JM. Research diagnosis for Tardive Dyskinesia. Archives of General Psychiatry 1982; 39: 486–487
- Kane JM, Jeste DV, Barnes TRE, Casey DE, Cole JO, Davis JM, Gualtier CT, Schooler NR, Sprague RL, Wettstein RM. American Psychiatric Association. Tardive Dyskinesia: A task force report of the American Psychiatric Association. APA, Washington, DC 1992
- Glazer W. Expected incidence of tardive dyskinesia associated atypical antipsychotics. Journal of Clinical Psychiatry 2000; 61(Suppl. 4)21–26
- Swainston Harrison T, Perry CM. Aripiprazole: A review of its use in schizophrenia and schizoaffective disorder. Drugs 2004; 64: 1715–1736
- British Medical Association & Royal Pharmaceutical Society of Great Britain. BMJ Publishing Group Ltd, London 2007
- Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics?. Movement Disorder 2006; 21: 589–598
- Jeste Glazer WM, Morgenstern H, Politz JA, Yeung PP. Rarity of tardive dyskinesia with quetiapine treatment of psychotic disorders in the elderly. Scientific book of abstracts, p. 142. The 38th Annual meeting of the American College of Neuropsychopharmacology. 12 December, 1999, 12–16